Kiss Industries LLC   Report issue

For profit Phase 4
Founded: Denver CO United States (2015)
Status: No NME R&D (2015)

Organization Overview

First Clinical Trial
2017
NCT03219840
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Alternative names

CONFADENT Oral Technology, Kiss Industries LLC

Active Ingredients

Drugs in Phase 4 Trials (1)

cetylpyridinium chloride (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Dental Plaque (Phase 4)

Gingivitis (Phase 4)

Periodontal Diseases (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 1
  • # of Trial APIs: 1